SEHK:6855Biotechs
Assessing Ascentage Pharma Group International’s Valuation After Recent Share Price Momentum
Recent share performance and business snapshot
Ascentage Pharma Group International (SEHK:6855) has drawn investor attention after recent share price moves, with returns of about 13% over the past week and 15% over the past month.
The Suzhou based clinical stage biotech focuses on therapies for cancers, chronic hepatitis B and age related diseases in Mainland China. It generated HK$574.12 million in revenue and reported a net loss of HK$1,242.77 million.
See our latest analysis for Ascentage...